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Iron overloadAbstract Background: HFE gene mutations have been shown to be responsible for hereditary
hemochromatosis. Their effect on iron load in b-thalassemia patients and carriers remains contro-
versial.
Objectives: We aimed to determine the prevalence of HFE gene mutations (C282Y and H63D) in
b-thalassemia patients and carriers and to investigate its effect on their serum ferritin levels.
Patients and methods: A total of 100 b-thalassemia subjects; 75 patients and 25 carriers were
screened for HFE gene mutations by PCR-RFLP. Serum ferritin measured by ELISA was evaluat-
ed in relation to HFE mutations.
Results: Twenty-eight b-thalassemia patients (37.3%) were heterozygotes for H63D mutation
(H/D), 8 (10.7%) were D/D and 39 (52%) were negative (H/H). Among carriers, 4 (16%) were
D/D and 21 (84%) were H/H homozygotes. C282Y mutant allele was not detected in any of the
subjects. Serum ferritin levels were signiﬁcantly higher in b-thalassemia patients heterozygotes or
homozygotes for H63D mutation compared to those without mutation (p= 0.000). Carriers
homozygotes for H63D mutation showed signiﬁcantly higher serum ferritin levels compared to
those without mutation (p< 0.001).
Conclusion: Homozygosity for H63D mutation tends to be associated with higher ferritin levels
in beta-thalassemia patients and carriers suggesting its modulating effect on iron load in these cases.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
b-Thalassemia constitutes a major public health problem in
Mediterranean countries [1]. In Egypt, it is the most common
chronic hemolytic anemia (85.1%) with a carrier rate of 5.3–
9% and annual birth of 1000/1.5 million live births [2].
130 M.M. Wilson et al.b-Thalassemia is associated with ineffective erythropoiesis
and ultimately iron overload [3], the later being the principal
and multifaceted complication of b-thalassemia. Physiological-
ly, iron overload is caused by increased iron absorption from
the gastrointestinal tract as a consequence of ineffective ery-
thropoiesis, and is greatly aggravated by chronic transfusion
therapy. Malfunctions of the hepcidin–ferroportin axis con-
tribute to the etiology of iron overload seen in thalassemia
[4]. A remarkable variability of tissue iron distribution has
been observed in b-thalassemia with liver, heart and endocrine
glands being the organs most severely affected [5]. Death from
cardiac failure is the most common clinical consequence of
iron excess. Therefore, effective iron chelation therapy is a cri-
tical component in the management of thalassemia [5].
Hereditary hemochromatosis, an autosomal recessive con-
dition involving iron metabolism, results in multiorgan toxic
iron overload [6]. Mutations in the HFE gene have been
reported to be responsible for primary hemochromatosis and
may play a role in the severity of secondary hemochromatosis
[7]. One of the commonest mutations in the HFE gene involves
a C to G substitution at nucleotide 187 that changes amino
acid 63 from histidine to aspartic acid (H63D). This mutation
has been reported to reduce the afﬁnity between transferrin
receptor and iron transferrin [8]. Another common mutation
includes the cysteine-to-tyrosine substitution at amino acid
282 in the HFE gene (C282Y mutation) [9].
The effect of these mutations on iron load in b-thalassemia
patients and carriers remains controversial. Interaction
between b-thalassemia and HFE gene mutations may increase
the likelihood of developing iron overload in thalassemic
patients [10]. Thus the impact of these mutations analysis on
the management of iron overload could be signiﬁcant, allowing
early accurate diagnosis and proper management to overcome
complications of secondary hemochromatosis [6].
This study aimed to determine the prevalence of HFE gene
mutations (C282Y and H63D) among b-thalassemia patients
and carriers and to investigate the effect of these mutations
on their serum ferritin levels.2. Subjects and methods
In this cross-sectional study, a total of 100 b-thalassemia sub-
jects; 75 b-thalassemia patients (homozygous or compound
heterozygous) and 25 carriers were screened for HFE gene
mutations (H63D and C282Y) by polymerase chain reaction-
restriction fragment length polymorphism method (PCR-
RFLP). Serum ferritin was measured for all subjects by
Microparticle Enzyme Immunoassay (AxSYM, Abbott,
USA) at diagnosis and b-globin gene mutations were also
determined by reverse hybridization technique. All b-tha-
lassemia patients (45 males and 30 females, mean age
3.2 ± 2.7 years) were diagnosed and followed at the Pediatric
Hematology Clinic of Cairo University. Diagnosis of b-tha-
lassemia was based on clinical presentation, hematological
indices, high performance liquid chromatography (HPLC)
[using the VARIANT II Beta-Thalassemia Short Program,
Bio-Rad Laboratories].
Their baseline serum ferritin at diagnosis was evaluated in
relation to the HFE mutations. Twenty-ﬁve heterozygotes
for b-thalassemia (12 males and 13 females, mean age
28.3 ± 3.9 years) attending for genetic screening or parentsor sibs of our patients were enrolled as carriers. All enrolled
subjects had no evidence of active liver disease or recent or pre-
sent infections or inﬂammatory illnesses that might affect fer-
ritin levels. All subjects or guardians gave informed consent
before enrollment. The study has been carried out in accor-
dance with The Code of Ethics of The World Medical Asso-
ciation (Declaration of Helsinki) for experiments in humans.
The study protocol was approved by the Ethics Committee
of the Cairo University.
2.1. Molecular testing
DNA was ﬁrst extracted from peripheral blood samples of the
affected children and their parents using QiAmp DNA blood
minikit (Catalogue No. 51104). Mutations were identiﬁed by
the reverse dot blot hybridization technique (RDB). For
RDB, a panel of probes (n= 22) using the beta globin strip
assay was used (b-Globin SripAssay MED kit, VIENNA
LAB, 116211, Austria) [11].
2.2. Detection of HFE gene mutations
Two primer sets were used for DNA ampliﬁcation, the ﬁrst, 50-
TGGCAAGGG0TAAACAGATCC-3 and 50-CTCAGGCAC-
TCCTCTCAACC-3 for the H63D mutation site and the sec-
ond, 50-ACATGGTTAAGGCCTGTTGC30 and 50-GCCA
CATCTGGCTTGAAATT-30) for the C282Y mutation site
[9]. PCR was performed using a Perkin Elmer Thermal Cycler
Gen Amp 9600 (Applied Biosystems, UK). A total volume of
25 ll PCR reaction containing 12.5 ll of ready-to-use PCR
Master Mix supplied by QIAGEN, Cat. No: 201443, 5.5 ll
of Nuclease-free water, 1 ll (20 pmol) of primer F, 1 ll
(20 pmol) of primer R and 5 ll (100 ng) of genomic extracted
DNA.
PCR cycles were 35 cycles of 96 C for 2 min, 96 C for 30 s,
56 C for 1 min, 72 C for 1 min and ﬁnal extension step of
72 C for 5 min. Ten micro liters of the PCR products were
subsequently digested with the restriction enzymes SnabI
Enzyme (Fast Digest SnabI) (C282Y mutation) supplied from
Fermentas Life Sciences, USA Reagents Code No. #FD1794
and BclI (H63D mutation) supplied by New England Biolab
reagent code No.: R0160S. The digestion products were elec-
trophoresed on a 3% gel (1:1 agarose/Nusiev). Ampliﬁcation
with the primers for codon 282 produced a 400 bp fragment
in the wild genotype, in the mutant genotype it would produce
2 fragments of 290 bp and 110 bp after endonuclease digestion.
On the other hand, the wild genotype of H63D mutation gives
a single band at 187 bp, the heterozygous H/D genotype gives
2 bands at 187 and 209 bp and the homozygous mutant D/D
genotype gives a single band at 209 bp [9], DNA size marker
(100 pb) was used (Thermo Scientiﬁc GeneRuler 100 bp Plus
DNA Ladder, ready-to-use #SM0323).
2.3. Statistical methods
Data were coded and entered using statistical package SPSS
version 17. Data were expressed as mean ± standard deviation
(±SD), median, range, frequencies and percentages when
appropriate. Numerical variables were compared using Stu-
dent t test for independent samples when normally distributed
and Mann Whitney U test when not normally distributed. For
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formed. One way ANOVA was used to test for differences
between groups. Signiﬁcance level was deﬁned as p< 0.05.
3. Results
b-Thalassemia patients showed signiﬁcantly lower mean hemo-
globin levels and higher median serum ferritin compared to
thalassemia carriers (7.9 ± 1.6 g/dl vs. 9.9 ± 2.3 g/dl; p val-
ue < 0.001 and 386 ng/ml vs. 216 ng/ml; p= 0.03 respective-
ly). The most prevalent underlying genetic mutations of b
globin gene in the b-thalassemia patients were IVS 1.110
(55%) followed by the IVS 1.6 (36%).
3.1. Prevalence of HFE gene mutations
Twenty-eight of 75 b-thalassemia patients (37.3%) were
heterozygotes for the H63D mutation (H/D), 8 (10.7%) were
D/D homozygotes and 39 (52%) were negative for the muta-
tion (H/H homozygotes). Among carriers, 4 (16%) were D/
D homozygotes and 21 (84%) were H/H homozygotes (Fig
1). The wild type (H/H genotype) presented at signiﬁcantly
higher frequency among carriers (p= 0.002), whereas the
mutant heterozygous genotype was signiﬁcantly more preva-
lent among thalassemia patients (p= 0.002) (Table 1). The
C282Y mutant allele was not detected in either the patients
or carriers.Figure 1 PCR polymorphisms of H63D mutation of HFE gene in
showing: Lane 4: Molecular weight marker 100 bp. Lanes 1, 2, 3 and 6:
Shows the H/D heterozygous genotype with 2 bands at 187 and 209 bp
genotype with a single band at 209 bp.
Table 1 Results of the PCR-RFLP demonstrating different p
b thalassemia
N= 75
Wild type (H/H genotype)
Number (%)
39 (52%)
Heterozygous (H/D genotype)
Number (%)
28 (37.3%)
Homozygous (mutant) (D/D genotype)
Number (%)
8 (10.7%)
* High statistical signiﬁcance.3.2. H63D gene polymorphisms and serum ferritin
Serum ferritin levels were compared to H63D genotypes in b-
thalassemia patients and carriers (Table 2). Serum ferritin
levels were signiﬁcantly higher in b-thalassemia patients who
were heterozygotes or homozygotes for the H63D mutation
compared to those without the mutation (p< 0.001). b-Tha-
lassemia carriers homozygotes for the H63D mutation showed
signiﬁcantly higher serum ferritin levels compared to those
without the mutation (p< 0.001).
3.3. H63D and b globin gene mutations
No statistically signiﬁcant relation between the H63D gene
mutation and genotype of the patients or the carriers (p> 0.05).
4. Discussion
Co-inheritance of HFE gene mutations may have a substantial
role in iron overload in b-thalassemia patients and carriers.
Results from different studies are rather conﬂicting. We hereby
report the prevalence of H63D mutations and the absence of
C282Y mutations among a cohort of 100 Egyptian b-tha-
lassemia patients and carriers. We also evaluated the effect
of these mutations on their steady state baseline serum ferritin
levels.b-thalassemia patients. PCR of H63D mutation in HFE gene
Shows the H/H wild genotype with a single band at 187 bp. Lane 5:
respectively. Lanes 7 and 8: Shows the D/D homozygous mutant
atterns of polymorphism of HFE: H63D polymorphism.
patients b thalassemia carriers
N= 25
P value
21 (84%) 0.002*
0 0.002*
4 (16%) 0.002*
Table 2 Serum ferritin levels in b-thalassemia patients and carriers according to their H63D genotype.
H63D genotype b-Thalassemia patients (n= 75) b-Thalassemia carriers (n= 25)
No. of subjects (%) Ferritin (ng/ml)
Mean ± SD
P value No. of subjects (%) Ferritin (ng/ml)
Mean ± SD
P value
H/H 39(52%) 297.2 ± 175.8 <0.001* 21(84%) 221.9 ± 142.9 <0.001*
H/D 28(37.3) 565.3 ± 358 – –
D/D 8(10.7%) 920.4 ± 508.2 4(16%) 969.8 ± 290.3
* P-values: H/H vs. H/D; H/D vs. D/D; H/H vs. D/D <0.001.
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between different populations; being highly prevalent among
European population [12], relatively less common in Brazil
[13], Japan [14] and Thailand [15]. Available data among
Egyptian population or thalassemia patients are rather limited.
In this study, the reported frequency of HFE gene mutations
was comparable to that in previous studies in Egyptian tha-
lassemia patients [16,17] and non-Egyptians populations with
different ethnic backgrounds whether thalassemia patients or
not [12,18,19]. However, in our study homozygous mutant
(D/D genotype) was detected among our thalassemia patients
and carriers (10.7% and 16% respectively) a ﬁnding which was
not reported in the previous Egyptian study [16], the number
of studied patients can explain this difference. Heterozygous
mutant genotype of H63D was more prevalent among our b-
thalassemia patients compared to carriers, however a more
extended study with higher number of carriers and patients
would be needed to conﬁrm this ﬁnding.
C282Y mutation was reported to be responsible for 60% of
hereditary hemochromatosis cases in the Mediterranean
population [20], with a North to South decrease in frequency
[21,22]. In a Brazilian cohort, a high frequency of C282Y
mutation among beta thalassemia patients suggested that it
may worsen the clinical picture of these individuals. C282Y
mutation was not detected in any of our patients or carriers
and this is in agreement with other studies among Egyptian
and non-Egyptian populations which reported the extreme rar-
ity or even the absence of C282Y mutation [10,16,18,23–25].
This discordance may be attributed to differences in racial
and ethnic backgrounds.
Despite advances in methods used to assess iron load in
thalassemia patients, serum ferritin measurement remains to
be the widely and most commonly used tool especially in devel-
oping countries. On comparing steady state serum ferritin
levels with H63D genotypes in our cohort, both homozygote
and heterozygote states showed signiﬁcantly higher levels of
serum ferritin among b-thalassemia patients. b-Thalassemia
carriers with the homozygote mutant genotypes had sig-
niﬁcantly higher serum ferritin levels than those with no muta-
tion. This may conﬁrm the possible role of H63D mutation in
increasing iron storage when in interaction with other genetic
determinants [26]. Two independent pathways have been pro-
posed to regulate iron metabolism, namely the erythroid
regulator, which modulates intestinal iron absorption in
response to the needs of the erythron, and the storage regula-
tor, which controls iron accumulation [27–29]. Despite the
hypothesis that the erythroid regulator (beta-thalassemia)
seems to be more pronounced than the storage regulator (the
defective HFE gene) in determining the degree of iron absorp-
tion [27,28], our results along with ﬁndings from other studies[18,30–32] support the observation that coinheritance of b-tha-
lassemia with heterozygosis or homozygosis for H63D are
associated with increased iron load. However, results are still
controversial [24,29,33,34].
The most prevalent underlying genetic mutations of b glo-
bin gene in our b-thalassemia patients and carriers were IVS
1.110 (55% and 44% respectively) followed by the IVS 1.6
(36% and 20% respectively). This goes in agreement with
other studies including similar ethnic groups [34–38]. This
study showed no correlation between these mutations and
the H63D genotype.
In conclusion, homozygosity for the H63D mutation tends
to be associated with higher ferritin levels in beta-thalassemia
patients and carriers. This suggests that this mutation may
have a modulating effect on iron load in these patients. Proper
and timely management prevents the hazard of iron overload.
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